AbCellera Biologics Inc. (ABCL): Strong Buy Stock with Potential for Growth

Friday, Jan 30, 2026 8:21 pm ET1min read
ABCL--

AbCellera Biologics Inc. (NASDAQ:ABCL) is a strong buy stock under $5, according to Wall Street analysts. The company announced the dosing of the first patients in its Phase 2 clinical trial for ABCL635, a potential treatment for menopause symptoms. Truist Financial reiterated a Buy rating on the stock. AbCellera Biologics solves antibody discovery problems and develops antibody medicines for various conditions. While ABCL has potential, certain AI stocks may offer greater upside potential and carry less downside risk.

AbCellera Biologics Inc. (ABCL): Strong Buy Stock with Potential for Growth

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet